IngredientsTropoflavin, also known as 7,8-dihydroxyflavone (7,8-DHF), is a naturally occurring flavone found in Godmania aesculifolia, Tridax procumbens, and Primula vulgaris. The compound is most commonly referred to in the scientific literature by the abbreviation 7,8-DHF, though the INN-style name tropoflavin has also been adopted. Its systematic chemical name reflects the position of its two hydroxyl substituents: 7,8-dihydroxy-2-phenyl-4H-chromen-4-one. Additional synonyms include 7,8-dihydroxy flavone and 7,8-Di-OH flavone. Its CAS Registry Number is 38183-03-8. Its molecular formula is C₁₅H₁₀O₄ and its molecular weight is 254.24 Da.
Due to the O-dihydroxy structure at the C7 and C8 positions of the A ring, this compound is rarely found in nature. The complete lack of oxygenation in the B-ring of the flavonoid skeleton and the common hydroxylation at C-5 position of the A-ring being absent — replaced instead by hydroxylation at C-8 — is evident in its structure. This unusual catechol motif distinguishes 7,8-DHF from the vast majority of dietary flavones, which typically carry hydroxyl groups at C-5 and C-7. The catechol group of 7,8-DHF is heavily processed in the liver by glucuronidation, sulfation, and methylation.
7,8-Dihydroxyflavone (7,8-DHF) is a naturally occurring flavonoid produced by several plants, including the weed Tridax procumbens (coalbuttons or tridax daisy) and the tree Godmania aesculifolia, which are found in the Western Hemisphere tropics, and trees in the widespread Primula genus. It has also been identified in Malus hupehensis. The compound is described as a rare flavonoid in nature: the O-dihydroxy structure at C7 and C8 positions of the A ring means this compound is rarely found in nature, and the natural quantities present in these plants are very small.
Because natural plant sources yield only trace amounts, this compound is now sourced through a synthetic route and has shown promise as a BDNF receptor (TrkB) agonist in potential neurogenesis as well as many other therapies. For research purposes, 7,8-DHF is typically handled as a crystalline powder with high purity (≥98%). It is soluble in DMSO, ethanol, and methanol. 7,8-DHF is a biologically active flavone with various physiological activities, including neuroprotection, anti-inflammation, and weight loss; however, the efflux protein P-glycoprotein (P-gp) significantly affects its transepithelial transport in the intestine, resulting in low oral bioavailability. To address pharmacokinetic shortcomings, researchers have developed a prodrug approach: a prodrug of tropoflavin with greatly improved potency and pharmacokinetics, R13 (and, formerly, R7), is under development for the treatment of Alzheimer's disease. Encapsulation strategies using nanoparticle delivery systems (e.g., zein-based composite nanoparticles) have also been explored in food science research to improve water solubility and bioaccessibility.
It is essential to distinguish 7,8-DHF as a specific, isolated molecule from the broader traditional uses of the plants from which it has been identified. 7,8-Dihydroxyflavone as a defined chemical entity was not known or used in any traditional medicine system. Its identification as a discrete bioactive compound occurred in the modern era of analytical chemistry. During the past decades, more than 190 preclinical publications have explored the efficacy of 7,8-DHF in animal models, with serious scientific attention commencing after a landmark 2010 publication in Proceedings of the National Academy of Sciences.
Tridax procumbens (tridax daisy), one of the plants in which 7,8-DHF has been identified, has its own distinct ethnobotanical history in South and Southeast Asia. T. procumbens has been used from ancient times to treat wounds, skin diseases, and to stop blood clotting in folk medicine. In Ayurvedic medicine, the flavonoid fraction of T. procumbens is recorded as a hepatic stimulant; the leaves and root bark are traditionally used for dropsy, anaemia, arthritis, and gout; and the plant is used for the treatment of asthma, ulcer, piles, and urinary problems. However, these traditional uses pertain to whole plant preparations and the plant's full phytochemical profile — not to isolated 7,8-DHF. No traditional therapeutic system has used or even identified 7,8-DHF as a distinct ingredient.
Primula species (primroses) have a parallel traditional presence in European herbal medicine, primarily as expectorants and for rheumatic conditions, again as whole plant preparations. No traditional use of Godmania aesculifolia medically pertaining to flavone isolation has been documented in the peer-reviewed literature.
The defining and most thoroughly investigated mechanism of 7,8-DHF is its direct agonism of the TrkB (tropomyosin receptor kinase B) receptor, the principal high-affinity receptor for the neurotrophin brain-derived neurotrophic factor (BDNF). Brain-derived neurotrophic factor (BDNF), a cognate ligand for the TrkB receptor, mediates neuronal survival, differentiation, synaptic plasticity, and neurogenesis; however, BDNF has a poor pharmacokinetic profile that limits its therapeutic potential. In this context, 7,8-DHF was identified as a bioactive high-affinity TrkB agonist that provokes receptor dimerization and autophosphorylation and activation of downstream signaling.
7,8-DHF acts as a TrkB agonist, which selectively binds to the extracellular domain of TrkB, but not TrkA, and stimulates its dimerization and autophosphorylation. More precisely, the binding of 7,8-DHF to the cysteine cluster 2 and leucine-rich region in the extracellular domain of the TrkB receptor provokes TrkB receptor dimerization and autophosphorylation, which leads to activation of downstream signaling cascades similar to BDNF. The compound's affinity for TrkB has been measured: it has been found to act as a potent and selective small-molecule agonist of the tropomyosin receptor kinase B (TrkB) with a Kd of approximately 320 nM, the main signaling receptor of the neurotrophin brain-derived neurotrophic factor (BDNF). Importantly, 7,8-DHF can bind to the TrkB receptor with high affinity and is able to pass the blood-brain barrier, making it a viable alternative to BDNF in therapeutic treatment.
A central motivation for studying 7,8-DHF is the inadequacy of BDNF itself as a therapeutic agent. The therapeutic potential of BDNF is restricted due to its short half-life (less than 10 minutes) and its inability to cross the blood-brain barrier because of its large size; unlike BDNF, 7,8-DHF is able to penetrate the blood-brain barrier and enter the central nervous system (CNS). Notably, compared to BDNF, DHF has a much longer half-life of approximately 4–8 hours in vivo in a primate model, compared to just 10 minutes for BDNF.
Upon TrkB engagement, 7,8-DHF activates three major intracellular signaling pathways: 7,8-DHF functions as a small molecule agonist of TrkB, effectively simulating the function of BDNF and activating downstream signaling pathways, including MAPK/ERK, PI3K/Akt, and PLCγ1/PKC; the activation of the MAPK/ERK pathway can stimulate neural differentiation, the PI3K/Akt pathway can promote neuron survival and growth, while PLCγ1/PKC signaling is crucial for synaptic plasticity. 7,8-DHF also stimulates Akt and ERK phosphorylation.
The selective phosphorylation pattern at the TrkB receptor differs from that of BDNF. The effect of 7,8-DHF through the TrkB receptor in striatum is via selective phosphorylation of its Y816 residue and activation of the PLCγ1 pathway, but pleiotropic effects of the drug also contribute to its therapeutic potential.
At the synaptic level, the mechanism of 7,8-DHF in improving learning and memory may be through activating BDNF-TrkB and downstream signaling pathways such as ERK, AKT, CaMKII, and CREB in specific brain regions, increasing the expression of synaptic proteins in the hippocampus, maintaining normal synaptic structure and function, delaying neuronal apoptosis and improving the survival rate of newborn neurons.
Beyond TrkB-mediated actions, 7,8-DHF exerts further biological effects. 7,8-DHF also increases the production of Nrf2, which in turn increases antioxidant enzymes such as heme oxygenase 1 (HO-1) and also enzymes that repair DNA (8-oxoguanine DNA glycosylase-1, OGG1). 7,8-DHF also has anti-neuroinflammation properties and increases hippocampal antioxidant capacity. In isolated cell and tissue experiments, the compound has been shown to modulate GABAergic neurotransmission: incubation of acute cortical slices with 7,8-DHF (20 µM) for 30 min caused a selective reduction in the strength of GABAergic inhibition. Additionally, 7,8-DHF was able to alter intrinsic neuronal excitability by significantly increasing spike frequency and input resistance, and all reported effects were abolished in the presence of the TrkB receptor antagonist K252a, indicating a direct involvement of TrkB receptors in the action of 7,8-DHF.
Orally administered 7,8-DHF is mainly metabolized via glucuronidation and methylation. In the plasma, both types of modified metabolites and parent 7,8-DHF were detectable, whereas in the brain, only 7,8-DHF and the 8-mono-methylated metabolite could be demonstrated. Both 7,8-DHF and its methylated metabolite provoked TrkB activation in mouse brain. Both hydroxy groups can be mono-methylated, and the mono-methylated metabolites activate TrkB in vitro and in vivo.
Important caveat: As of the time of writing, the overwhelming majority of published evidence for 7,8-DHF consists of preclinical (animal model and cell culture) studies. No completed, published randomized controlled clinical trials in humans have been identified in the peer-reviewed literature for 7,8-DHF as an isolated compound. During the past decades, more than 190 preclinical publications have explored the efficacy of 7,8-DHF in animal models. All specific study findings below derive from animal or in vitro models unless otherwise stated, and the evidence must be characterized accordingly as preliminary and not yet established for human therapeutic use.
The largest body of preclinical work on 7,8-DHF concerns its effects on learning and memory. Systemic administration of 7,8-DHF can activate TrkB receptors in brains and induce BDNF-like behavioral phenotypes, such as enhanced learning and memory, and antistress or antidepressant-like effects in rodents in a TrkB-dependent manner.
In a study using wildtype mice (i.e., animals without any disease model), 7,8-DHF is a low molecular weight compound that can cross the blood-brain barrier and has been implicated in numerous functions and behaviors; it is thought to have neuroprotective capability. The compound was administered systemically to wildtype mice during Morris water maze training, and long-term spatial memory was assessed 28 days later. The study found that systemic 7,8-DHF administration during the training period enhanced spatial memory 28 days later, and volumetric changes were observed in numerous brain regions associated with a broad range of functions including cognition, sensory, and motor processing.
In research involving impaired spatial memory due to reduced oligodendrogenesis, mice with reduced adult oligodendrogenesis in the Morris water maze, a test of spatial learning, were found to have impaired long-term (28-day) spatial memory; however, when 7,8-DHF was administered immediately after each training session, their long-term spatial memory impairment was rescued, and an increase in the number of newly formed oligodendrocytes in the corpus callosum was also observed. Across the literature, 7,8-DHF has previously been shown to improve spatial memory in animal models of Alzheimer's disease, post-traumatic stress disorder, Wolfram syndrome, and Down syndrome, as well as in normal aging.
Evidence strength: Consistent across multiple animal studies. No human clinical data available. Effects in healthy humans remain untested.
Increasing evidence suggests that reductions in BDNF and its receptor TrkB may have a role in the pathogenesis of Alzheimer's disease (AD). In a study using the 5XFAD transgenic mouse model of AD, 7,8-DHF, a recently identified small-molecule TrkB agonist that can pass the blood-brain barrier, was evaluated in 5XFAD transgenic mice. Mice at 12–15 months of age and non-transgenic littermate controls received systemic administration of 7,8-DHF (5 mg/kg, i.p.) once daily for 10 consecutive days. 7,8-DHF rescued memory deficits of 5XFAD mice in the spontaneous alternation Y-maze task.
A separate study using the same transgenic model at an earlier age examined chronic oral treatment: two-month-old 5XFAD mice were treated with 7,8-DHF (5 mg/kg/day) or vehicle consecutively for 4 months. The level of p-TrkB, p-AKT and p-ERK/MAPK was increased by 7,8-DHF treatment, indicating that 7,8-DHF elicits TrkB and its downstream signaling pathways. After extensive validation, 7,8-DHF was identified as a selective small-molecular TrkB agonist that mimics the physiological actions of BDNF. Chronic oral administration of 7,8-DHF exerted therapeutic effect in 5XFAD mice, an effect largely attributed to the protective effect of 7,8-DHF on synapses — identifying 7,8-DHF as a novel "synaptoprotective" strategy for the treatment of AD and other neurodegenerative diseases.
7,8-DHF has only modest oral bioavailability and a moderate pharmacokinetic (PK) profile. To alleviate these preclinical obstacles, a prodrug strategy for elevating 7,8-DHF oral bioavailability and brain exposure was used, and the optimal prodrug R13 was found to have favorable properties and dose-dependently reverses the cognitive defects in an AD mouse model.
Evidence strength: Multiple independent animal studies show consistent reversal of memory deficits. No human studies. A prodrug (R13) is in developmental stages but no clinical trial data are publicly available.
Administration of 7,8-DHF to mice activated TrkB in the brain and was neuroprotective in an animal model of Parkinson's disease. In cell and animal models, it reduces striatal nigral neuronal apoptosis in a mouse model of MPTP-induced Parkinson's disease. A rat model study found that 7,8-DHF was found to protect against loss of dopaminergic neurons in the substantia nigra and striatum and improve open field locomotion in a rat model of Parkinson's disease.
Evidence strength: Preclinical only; no human data.
Huntington's disease (HD) is a fatal neurodegenerative disease with motor, cognitive, and psychiatric impairment. Dysfunctions in HD models have been related to reduced levels of striatal BDNF and imbalance between its receptors TrkB and p75NTR; thus, molecules with activity on the BDNF/TrkB/p75 system can have therapeutic potential. 7,8-DHF has been studied in HD mouse models. 7,8-DHF was found to enhance the survival of cultured motor neurons and improved motor function in a mouse model of Huntington's disease. The PLCγ1 signaling pathway appears to mediate key effects: the effect of 7,8-DHF through the TrkB receptor in striatum is via selective phosphorylation of its Y816 residue and activation of the PLCγ1 pathway, but pleiotropic effects of the drug also contribute to its therapeutic potential.
Evidence strength: Preclinical only; consistent across multiple animal studies; no human data.
Multiple preclinical studies have examined 7,8-DHF in animal models of depression. 7,8-DHF crosses the blood-brain barrier, restores the abnormal BDNF-TrkB signaling pathway in the prefrontal cortex and hippocampus, activates the downstream AKT-mTOR and MAPK-ERK pathway, and increases the expression of synaptic proteins (PSD95 and synaptophysin), thus exerting anti-depressive effects.
In a study using the chronic mild stress (CMS) paradigm in rats: four-week CMS on the rats induced depression-like behavior in the sucrose consumption test. The CMS-reduced sucrose consumption was reversed starting from 7 days after 7,8-dihydroxyflavone (20 mg/kg) treatment and remained across the subsequent treatment regime. 7,8-DHF, when given at 5 mg/kg for 3 weeks, reduced the immobility time in the forced swim test in CMS-subjected rats. Additionally, the 4-week treatment with 7,8-DHF (20 mg/kg) attenuated the CMS-induced increase in anxiety-like behavior. 7,8-DHF treatment dose-dependently reduced serum corticosterone levels but increased hippocampal BDNF levels only at 5 mg/kg.
A separate study comparing 7,8-DHF with ketamine in a social defeat stress model found that in the tail suspension and forced swimming tests, ketamine, 7,8-DHF, or ANA-12 markedly attenuated the increased immobility time in depressed mice compared with the vehicle-treated group. However, the antidepressant effect of ketamine, but not 7,8-DHF or ANA-12, was still detectable 7 days after a single dose, suggesting a shorter duration of action for 7,8-DHF.
Further corroborating the TrkB dependence of these antidepressant effects: the TrkB antagonist K252a blocked the antidepressant-like effects of 7,8-DHF. Chronic 7,8-DHF treatment exerted significant antidepressant-like effects, which were likely attributed to regulating TrkB signaling and thus promoting synaptic protein expression.
Evidence strength: Robust and consistent in multiple animal models of depression using different paradigms (CMS, social defeat, forced swim). No published human clinical trials. Duration of effect appears shorter than some comparators in animal data.
7,8-DHF effectively alleviates PTSD-like symptoms, including fear generalization and anxiety-like behavior, potentially by preventing astrocytic and synaptic deficits in the hippocampus through targeting of TrkB. Acute or continuous intraperitoneal administration of 7,8-DHF (5 mg/kg) after single prolonged stress procedures prevented induced fear memory generalization and anxiety-like behaviors as well as abnormalities of hippocampal oscillations. Most importantly, 7,8-DHF attenuated induced abnormal BDNF-TrkB signaling and calpain-1-dependent cascade of synaptic deficits.
Earlier emotional learning research demonstrated that a fuller understanding of the BDNF/TrkB system had been limited by the lack of any identified small-molecule TrkB agonists that fully mimic the actions of BDNF at brain TrkB receptors in vivo; however, 7,8-DHF has been identified as a specific TrkB agonist that crosses the blood-brain barrier after oral or intraperitoneal administration.
Evidence strength: Preclinical only; consistent across fear-conditioning and PTSD paradigms in rodents; no human trials.
The present study investigated the effects and underlying mechanisms of TrkB activation by 7,8-DHF on traumatic brain injury (TBI). Mice subjected to controlled cortical impact received intraperitoneal 7,8-DHF or vehicle injection 10 min post-injury and subsequently daily for 3 days. Treatment with 20 mg/kg 7,8-DHF attenuated functional deficits and brain damage up to post-injury day 28. 7,8-DHF also reduced brain edema, neuronal death, and apoptosis at day 4. The mechanism was identified as 7,8-DHF-induced brain tissue protection in CCI brains is mediated through TrkB and downstream PI3K/Akt pathways.
Evidence strength: Preclinical only; no human data. Although the therapeutic potential of 7,8-DHF has been reported in varying types of neurological diseases, its use for TBI has just begun to be explored in TBI models; thus far, a handful of published studies have tested the effect of 7,8-DHF in TBI models.
Administration of 7,8-DHF to mice activated TrkB in the brain, inhibited kainic acid-induced toxicity, and decreased infarct volumes in stroke in a TrkB-dependent manner. At a cellular level, 7,8-DHF treatment increased cell viability and reduced neuronal apoptosis following oxygen-glucose deprivation; 7,8-DHF treatment downregulated Bax and cleaved caspase-3 but upregulated Bcl-2, and these changes were accompanied by a significant increase in the phosphorylation of TrkB and Akt.
Evidence strength: In vitro and rodent model data only; no human clinical evidence.
7,8-DHF has been studied in animal models of several neurodevelopmental conditions. Administration of 7,8-DHF elongates the lifespan and alleviates the pathological conditions of Rett syndrome. 7,8-DHF has been found to improve symptoms in animal models of Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, traumatic brain injury, post-traumatic stress disorder, depression, Wolfram syndrome, Down syndrome, and an in vitro model of ischemic stroke. In ALS models, improvement in motor deficits was seen in an ALS mouse model along with increased numbers of motor neurons and dendritic spines in the lumbar spinal cord.
In a multiple sclerosis model, C57Bl/6 mice with MOG-induced EAE were treated daily with DHF starting on the day of disease induction; clinical severity of impairment was reduced throughout the course of disease.
Evidence strength: All findings are from animal or in vitro models. In no case has efficacy been demonstrated in human clinical trials for these conditions.
Chronic activation of TrkB is a potential method to prevent development of obesity, but the short half-life and non-bioavailable nature of BDNF hampers validation of the hypothesis. Activation of muscular TrkB by the BDNF mimetic 7,8-DHF is sufficient to protect against the development of diet-induced obesity in female mice. Using in vitro and in vivo models, 7,8-DHF treatment enhanced the expression of uncoupling protein 1 (UCP1) and AMP-activated protein kinase (AMPK) activity in skeletal muscle, which resulted in increased systemic energy expenditure, reduced adiposity, and improved insulin sensitivity in female mice fed a high-fat diet. This antiobesity activity of 7,8-DHF is muscular TrkB-dependent, as 7,8-DHF cannot mitigate diet-induced obesity in female muscle-specific TrkB knockout mice.
Importantly, the metabolic effects were sex-dependent: 7,8-DHF confers protection against high-fat diet-induced metabolic pathologies selectively in female mice; this metabolic protection is associated with early and stable remodeling of the intestinal microbiome, evident in female but not male DHF-supplemented mice. Early changes in the gut microbiome in female DHF-fed mice were highly predictive of subsequent metabolic protection, suggesting a causative association between the gut microbiome and the metabolic effects of DHF.
Evidence strength: Preclinical only; notable sex-dependent effects; no human studies published.
In vivo, in a model of chronic intermittent hypoxia in the retina, DHF reduces the production of reactive oxygen species (ROS), activates TrkB signals and downstream AKT and ERK signaling pathways, and upregulates the expression of mature BDNF, alleviating retinal ganglion cell (RGC) damage. In a rat model of optic nerve axotomy, DHF has a potent in vivo neuroprotective effect for RGCs against injury, at an optimal dose of 5 mg/kg administered intraperitoneally; the percentages of surviving Brn3a⁺ RGCs in vehicle- or DHF-treated rats one week after injury were 60 and 94%, respectively.
Evidence strength: Preclinical only; no human ophthalmic trials reported.
All dosages below are drawn directly from published preclinical studies and pharmacokinetic research. No established human clinical dosage exists.
The catechol group of 7,8-DHF is heavily metabolized in the liver by glucuronidation, sulfation, and methylation, resulting in a low oral bioavailability of 4.6%. The average in vivo half-life of molecules containing catechol is only approximately 134 minutes. After a single administration, the antidepressant effect of 7,8-DHF dissipates within seven days.
The prodrug R13 was developed specifically to address these limitations: the mean value of oral bioavailability for R13 was 10.5%. The 7,8-DHF T½ released from R13 was 219.6 min versus 134 min by the parent compound, indicating the prodrug can sustainably release 7,8-DHF in the circulation system.
Absorption in the intestine is significantly constrained by P-glycoprotein efflux. The efflux protein P-glycoprotein (P-gp) significantly affects the transepithelial transport of 7,8-DHF in the intestine, resulting in its low oral bioavailability. Kaempferol and quercetin exhibited the best effect on promoting the transepithelial transport of 7,8-DHF, especially when used at molar concentration ratios of 1:1 and 1:2 with 7,8-DHF. 7,8-DHF was found to maintain structural stability in simulated saliva, gastric juice, and intestinal juice.
In preclinical studies, 7,8-DHF has been administered via intraperitoneal (i.p.) injection, oral gavage, and dissolved in drinking water. No standardized human oral dosage form has been established or clinically validated. Supplement products marketed for human consumption exist but are not backed by clinical trial dosage data.
7,8-DHF has a favorable biosafety profile and exhibits no observable toxicity even after prolonged oral use. This assessment, however, is based on preclinical studies; no systematic human safety or toxicology study has been published. 7,8-DHF has only modest oral bioavailability and a moderate pharmacokinetic (PK) profile, which is a recognized limitation rather than a safety advantage per se.
7,8-DHF has certain disadvantages because it includes catechol groups with innate pharmacokinetic abnormalities; the catechol group of 7,8-DHF is heavily processed in the liver by glucuronidation, sulfation, and methylation, resulting in the low oral bioavailability of 4.6%. The metabolism of 7,8-DHF involves catechol-O-methyltransferase (COMT): the blockade of COMT transferase inhibits the methylation of 7,8-DHF and reduces the agonistic activity by 7,8-DHF in mouse brain. This implies that co-administration of COMT inhibitors — a class of drugs used in Parkinson's disease therapy — could alter the pharmacological activity of 7,8-DHF by interfering with its active metabolite formation.
Absorption interactions have been identified at the P-glycoprotein efflux transporter level. Kaempferol and quercetin, acting as P-gp inhibitors, could boost 7,8-DHF transport in Caco-2 cells; quercetin as a P-gp inhibitor could promote 7,8-DHF transport. This raises the possibility that co-ingestion of quercetin- or kaempferol-rich foods or supplements could increase 7,8-DHF intestinal absorption, a pharmacokinetically relevant consideration that has not yet been studied in humans.
Preclinical evidence indicates sex-dependent differences in response. The plasma and brain pharmacokinetics of 7,8-DHF in neonatal mice were similar between males and females; the sex-biased neuroprotective effects of 7,8-DHF observed in prior studies are likely due to pharmacodynamic differences rather than PK. The metabolic/antiobesity effects have only been reproduced in female, not male, mice, requiring consideration in translational research planning.
No published randomized controlled trials, dose-escalation safety studies, or pharmacovigilance data in humans are currently available for 7,8-DHF as an isolated supplement or investigational drug. Pharmacokinetic knowledge may help in selecting dosing regimens needed to achieve target exposures that maximize efficacy and minimize toxicity, advancing the translation of 7,8-DHF therapy from preclinical to clinical studies, indicating that clinical translation is anticipated but not yet achieved. More than 190 preclinical publications have explored the efficacy of 7,8-DHF in animal models; this breadth of animal data has not yet been matched by human evidence.
Because 7,8-DHF activates TrkB — a receptor tyrosine kinase involved in cell growth and survival signaling — theoretical oncological considerations have been raised in the scientific literature regarding long-term, sustained TrkB activation. This is a recognized general concern with trophic factor signaling but has not been substantiated in any published toxicity study of 7,8-DHF. Similarly, because BDNF/TrkB signaling affects appetitive behavior, mood, and energy homeostasis, pleiotropic effects beyond the intended target are possible in human use but remain unstudied.
The recognition of 7,8-DHF's pharmacokinetic limitations has driven active research into structural modification and prodrug strategies. A prodrug of tropoflavin with greatly improved potency and pharmacokinetics, R13 (and, formerly, R7), is under development for the treatment of Alzheimer's disease. A prodrug strategy for elevating 7,8-DHF oral bioavailability and brain exposure identified the optimal prodrug R13; a large number of 7,8-DHF derivatives were synthesized via ester or carbamate group modification on the catechol ring in the parent compound, and using in vitro absorption, distribution, metabolism, and excretion assays combined with in vivo PK studies, R13 was identified as prominently upregulating 7,8-DHF PK profiles.
Health conditions that 7,8-dihydroxyflavone may help support.
Body systems that 7,8-dihydroxyflavone may help support.
Go back